Research Article

Preservation of Haemostasis with Anti-thrombotic Serotonin Antagonism

Mark IM Noble* and Angela J Drake-Holland

Published: 09/18/2017 | Volume 1 - Issue 1 | Pages: 019-025

Abstract

An enquiry into the lack of attention awarded to serotonin antagonism in the treatment of arterial thrombosis revealed that the mode of action of serotonin and its platelet receptor antagonists was an action upon thrombus growth, and not, as with other anti-platelet drugs upon the initiation of thrombosis. This lack of effect could explain why this approach has been considered not to be effective. However under conditions of arterial stenosis in which there is platelet activation by increased shear stress, and during the growth phase of arterial thrombi, serotonin 5HT2A antagonism has been demonstrated to have great potentcy in dispersing thrombotic obstruction to blood flow. This mode of action, the lack of participation of serotonin in haemostasis, and the absence of serotonin in wounds accounts for the proven lack of effect of effect of pure specific 5HT2A antagonists (i.e., not those with other actions) on operative bleeding and skin bleeding times. This lack of effect on haemostasis solves the dosing problem encountered with other anti-thrombotic drugs, with which drug concentration cannot be controlled with single fixed doses, leading to the association between increased anti-thrombotic efficacy and increased bleeding complications. Thus 5HT2A antagonism appears to be the preferred approach, from the point of view of safety and lack of bleeding risk; this consideration applies particularly to thrombosis therapy in the context of traumatic accidents, surgical operations and invasive procedures such as angioplasty.

Read Full Article HTML DOI: 10.29328/journal.jhcr.1001004 Cite this Article

References

  1. Noble MIM. Thrombosis as a unitary hypothesis of cardiovascular risk. J Cardiovasc Risk. 1995; 2: 177-179. Ref.: https://goo.gl/p8t1XC
  2. Steinhubi SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs. 2005; 5: 399-408. Ref.: https://goo.gl/dpxsc8
  3. De Meyer SF, Vanhoorelbeke K, Broos K, Salles II, Deckmyn H. Antiplatelet drugs. Br J Haematol. 2008; 142: 515-528. Ref.: https://goo.gl/af7yNg
  4. Jennings LK. Mechanisms of platelet activation: need for new stratgies to protect against platelet- mediated atherothrombosis. Thromb Haemost. 2009; 102: 248-257. Ref.: https://goo.gl/ogSSLa
  5. Belcher PR, Drake-Holland AJ, Hynd JW, Noble MIM. Failure of thrombin inhibition to prevent intracoronary thrombosis in the dog. Clin Sci (Lond). 1996; 90: 363-368. Ref.: https://goo.gl/nR7GY7
  6. Noble MIM, Drake-Holland AJ. The involvement of serotonin in the formation of thrombi at critical coronary artery stenoses in humans. Coronary Artery Disease. 1990; 1: 675-679. Ref.: https://goo.gl/uoVgST
  7. Noble MIM, Drake-Holland AJ. The possible role of serotonin 5HT2 receptor antagonism in cardioprotection. Neth J Med. 1992; 41: 183-189. Ref.: https://goo.gl/r92Eid
  8. Noble MIM, Drake-Holland AJ. The role of serotonin 5HT2 receptor antagonism in the control of coronary artery disease. Q J Med. 1994; 87: 11-16. Ref.: https://goo.gl/wbKmLj
  9. Torr S, Noble MIM, Folts JD. Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by the specific serotonin 5HT2 receptor antagonist ritanserin. Cardiovasc Res. 1990; 24: 465-470. Ref.: https://goo.gl/KtDHLQ
  10. Moerland M, Kemme M, Dijkmans A, Bergougnan L, Burrggraaf J. Modulation of vasoactivity and platelet aggregation by selective 5-HT receptor antagonism in humans. J Cardiovasc Pharmacol. 2011; 58: 575-580. Ref.: https://goo.gl/SWQNk3
  11. Goto S. Understanding the mechanism and prevention of arterial occlusive thrombus formation by anti-platelet agents. Curr Med Chem cardiovasc Hematol Agents. 2004; 2: 149-156. Ref.: https://goo.gl/Y1DNq4
  12. Van Nueten JM, Leysen JE, de Clerk F, Vanhoutte PM. Serotonergic receptor subtypes and vascular reactivity. J Cardiovasc Pharmacol. 1984; 6: 564-574. Ref.: https://goo.gl/L7ZWWZ
  13. Hara H, Osakabe M, Kitajima A, Tamao Y, Kikumoto R. MCI-9042, a new antiplatelet agent is a selective s2-serotonergic receptor antagonist. Thromb Haemost.  1991; 65: 415-420. Ref.: https://goo.gl/d2UEfd
  14. Golebiewska EM, Poole AW. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev. 2015; 29: 153-162. Ref.: https://goo.gl/LpvjB1
  15. Brenner B, Harney JT, Ahmed BA, Jeffus BC, Unal R, et al. Plasma serotonin levels and the platelet transporter. J Neurochem. 2007; 102: 206-215. Ref.: https://goo.gl/UErvuT
  16. Menys VC, Smith CCT, Lewins P, Farmer RDT, Noble MIM. Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin Sci (Lond). 1996; 91: 87-92. Ref.: https://goo.gl/WMAFSu
  17. Cerrito F, Lazzaro MP, Gaudio E. Arminio P, Aloisi G. 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci. 1993; 53: 209-215. Ref.: https://goo.gl/igVXKw
  18. De Clerck F. The role of serotonin in thrombogenesis. Clin Physiol Biochem. 1990; 3: 40-49. Ref.: https://goo.gl/F4fTL4
  19. Belcher, PR, Drake-Holland AJ, Hynd J, Noble MIM. Dispersion of coronary artery thrombi by antagonism of platelet serotonin receptor in the dog. Cardiovasc Res. 1992; 26: 292-296. Ref.: https://goo.gl/no2Kz5
  20. McAuliffe SJG, Snow HM, Cox B, Smith CTT, Noble MIM. Interaction between the effect of 5-hydroxytryptamine and adrenaline on the growth of platelet thrombi in the coronary artery of the anaesthetised dog. Br J Pharmacol. 1993; 109: 405-410. Ref.: https://goo.gl/QqDdHK
  21. Belcher PR, Drake-Holland AJ, Noble MIM. Antagonism of the platelet 5HT2 receptor in the presence of thrombolysis. Int J Cardiol. 1994; 43: 11-20. Ref.: https://goo.gl/gZmge7
  22. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. Circulation. 1999; 100: 483-489. Ref.: https://goo.gl/7zZC32
  23. Millson DS, Jessop CL, Swaisland A, Haworth S, Rushton A, et al. The effect of a selective 5HT2 receptor antagonist (ICI 170,809) on platelet aggregation and puplillary responses in healthy volunteers. Br J Clin Pharmacol. 1992; 33: 281-288. Ref.: https://goo.gl/59y1WZ
  24. Vandeplassche G, Hermans C, Van Dael L, Wouters l, De Clerke F. Interplay between platelet- derived 5HT and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine plateler-rich coronary thrombosis. J Cardiovasc Pharmacol. 1993; 21: 56-69. Ref.:
  25. https://goo.gl/Ub8Nsw
  26. Yamada K, Niki H, Nagai H, Nishikawa M, Nakagawa H. Serotonin potentiates high-glucose- induced endothelial injury: the role of serotonin and 5-HT2A recptors in promoting thrombosis in diabetes. J Pharmacol Sci. 2012; 119: 243-250. Ref.: https://goo.gl/sWYXP4
  27. Ashton JH et al. Serotonin as a mediator of cyclical flow variation in stenosed canine coronary arteries. Circulation. 1986; 73: 572-578. Ref.: https://goo.gl/FSZqUp
  28. Kirchengast M, Rubsamen K & Lehmann HD. Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993; 22: 687-694. Ref.:
  29. https://goo.gl/GS6naX
  30. Hsieh CP, Sakai K, Bruns GC, Dage RC. Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs. J Cardiovasc Pharmacol. 1994; 24: 761-772. Ref.: https://goo.gl/otkqNv
  31. Pawlak D, Pawlak K, Chabielska E, Malyszko J, Takada A, et al. A potent 5HT receptor (5-HT2A) antagonist, DV-7028, delays arterial thombosis development in rats. Thromb Res. 1998; 90: 259-270. Ref.: https://goo.gl/YjmaUJ
  32. Kihara H, Koganei H, Hirose K, Yamamoto H, Yoshimoto R. Antithrombotic activity of AT-1015, a potent 5-HT2A recptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. Eur J Pharmacology. 2001; 21:157-162. Ref.: https://goo.gl/beQVVZ
  33. Rashid M, Watanobe M, Nakazawa M, Nakamura T, Hattori K, et al. Assessment of affinity and dissociation of newly synthesized 5-HT2 antagonist, AT-1015: comparison with other 5-HT2 antagonists. Jpn J Pharmaccol. 2001; 87: 189-194. Ref.: https://goo.gl/vXf67z
  34. Adams JW et al. APD791, a novel 5HT2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. J Pharmacol Exp Ther. 2009; 331: 96-103. Ref.: https://goo.gl/2QSs3x
  35. Przyklenk K, Frelinger AL3rd, Linden D, Whittaker P, Li Y, et al. Targeted inhibition of the serotonin 5HT2 receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost. 2010; 8: 331-340. Ref.: https://goo.gl/4VAofo
  36. Xiong Y, Teegarden BR, Choi JS, Strah-Pleynet S, Decaire M, et al. Discovery and structure- activity relationship of APD791: a highly selective 5HT2A receptor inverse agonist for the treatment of arterial thrombosis. J Med Chem. 2010; 53: 4412-4421. Ref.: https://goo.gl/uDj4Sh
  37. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor-and imipramine-controlled trials. J Clin Psychiatry. 2001; 62: 256-260. Ref.: https://goo.gl/1dwes2
  38. Nagatomo T, Rashid M, Abul Muntasir A, Komiyama T. Functions of 5HT2A receptor and its antagonists in the cardiovasclar system. Pharmacol Ther. 2004; 104: 59-81. Ref.: https://goo.gl/gtj7DR
  39. Sakariassen KS, Hanson SR, Cadroy Y. Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. Thromb Res. 2001; 104: 149-174. Ref.: https://goo.gl/rGTRT1
  40. Valentin JP, View S, Bertolino F, Faure´P, John G. Differential involvement of serotonin 2A/C and thromboxane A2/prostenoid receptors in high- vs. low-shear rate arterial thrombosis in rabbits. J Pharmacol Exp Ther. 1997; 280: 761-769. Ref.: https://goo.gl/mQpcsf
  41. Stott DJ, Saniabadi AR, Hosie J, Lowe GDO, Ball SG. The effects of the 5HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension. Eur J Clin Pharmacol. 1988; 35: 123-129. Ref.: https://goo.gl/mwFrbY
  42. Vincentelly A, Jude B, Belisle S. Antithrombotic therapy in cardiac surgery. Can J Anaesth. 2006; 53: 89-102. Ref.: https://goo.gl/CxjDgU
  43. Lin OA, Karim ZA, Vemana HP, Espinosa EV, Khasawneh FT. The antidepressant 5-HT2A receptor antagonists piztifen and cyproheptadine inhibit serotonin-enhanced platelet function. PLoS One. 2014; 23: 87026. Ref.: https://goo.gl/E8J4zh
  44. Adams JW, Ramirez J, Ortuno D, Shi Y, Thomsen W, et al. Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist. Eur J Pharmacol. 2008; 586: 234-243. Ref.: https://goo.gl/h535k1
  45. Noble MIM, Ford I, Cameron G, Drake-Holland AJ. The novel anti-thrombotic drug with no bleeding excess. J Cardiol Cardiovasc Therap. 2017.